Merck is playing defense against Summit Therapeutics with a $3.3 billion licensing deal announced Thursday for a cancer drug from China's LaNova Medicines. Please watch the video at Investors.com ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback